Vir Biotechnology, Inc. (VIR) — Fair Value Analysis

Base-case fair value (P50): $8.32 · Current price: $9.12 · Verdict: Fairly Valued

The Verdict on VIR

Based on our probabilistic Monte Carlo simulations, VIR BIOTECHNOLOGY INC (VIR) is currently Fairly Valued. The stock trades at $9.12, while our median fair value (P50) stands at $8.32. This implies a -8.8% difference, suggesting that the market price is closely aligned with our valuation models, neither significantly over nor underpriced at this juncture. Investors should note this tight convergence when evaluating new positions.

How VIR stacks up against peers

Despite its Fairly Valued status, VIR's operational and financial health registers as "weak" within our quality tier assessment. This "weak" rating indicates underlying challenges relative to its sector peers, which could impact future performance trajectories. While the current price of $9.12 is near our $8.32 median fair value, the -8.8% gap coupled with a "weak" quality tier underscores a lack of significant cushion or upside potential without fundamental improvements.

What this means for investors

The assessment that VIR is Fairly Valued at its current price of $9.12, with a median fair value of $8.32, means our models do not indicate a compelling mispricing. The -8.8% gap suggests that any significant moves would likely require a shift in underlying fundamentals, especially given the "weak" quality tier. Investors are advised to consider the limited margin between the current price and our calculated P50. For a complete understanding, including the full bear and bull distribution and to track VIR's fair value as new fundamentals are released, sign up for a free FairCurve account.